![Avelumab timeline from discovery to Merck-Pfizer Alliance, breakthrough... | Download Scientific Diagram Avelumab timeline from discovery to Merck-Pfizer Alliance, breakthrough... | Download Scientific Diagram](https://www.researchgate.net/publication/316110412/figure/fig1/AS:602074563747840@1520557170452/Avelumab-timeline-from-discovery-to-Merck-Pfizer-Alliance-breakthrough-status-and-phase.png)
Avelumab timeline from discovery to Merck-Pfizer Alliance, breakthrough... | Download Scientific Diagram
![PDF] Avelumab: clinical trial innovation and collaboration to advance anti-PD-L1 immunotherapy | Semantic Scholar PDF] Avelumab: clinical trial innovation and collaboration to advance anti-PD-L1 immunotherapy | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/63896bbe64c237acb7d4260c2e84ab3aa4969933/35-Figure1-1.png)
PDF] Avelumab: clinical trial innovation and collaboration to advance anti-PD-L1 immunotherapy | Semantic Scholar
![Anti-PD-L1 antibodies atezolizumab, avelumab and durvalumab currently... | Download Scientific Diagram Anti-PD-L1 antibodies atezolizumab, avelumab and durvalumab currently... | Download Scientific Diagram](https://www.researchgate.net/publication/327840656/figure/fig5/AS:674379453190149@1537795999261/Anti-PD-L1-antibodies-atezolizumab-avelumab-and-durvalumab-currently-in-clinical.png)
Anti-PD-L1 antibodies atezolizumab, avelumab and durvalumab currently... | Download Scientific Diagram
![Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial | Nature Medicine Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial | Nature Medicine](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41591-020-1044-8/MediaObjects/41591_2020_1044_Fig1_HTML.png)
Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial | Nature Medicine
![Avelumab timeline from discovery to Merck-Pfizer Alliance, breakthrough... | Download Scientific Diagram Avelumab timeline from discovery to Merck-Pfizer Alliance, breakthrough... | Download Scientific Diagram](https://www.researchgate.net/publication/316110412/figure/fig1/AS:602074563747840@1520557170452/Avelumab-timeline-from-discovery-to-Merck-Pfizer-Alliance-breakthrough-status-and-phase_Q320.jpg)
Avelumab timeline from discovery to Merck-Pfizer Alliance, breakthrough... | Download Scientific Diagram
![Impact of subsequent immune checkpoint inhibitor treatment on overall survival with avelumab vs docetaxel in platinum-treated advanced NSCLC: Post hoc analyses from the phase 3 JAVELIN Lung 200 trial - Lung Cancer Impact of subsequent immune checkpoint inhibitor treatment on overall survival with avelumab vs docetaxel in platinum-treated advanced NSCLC: Post hoc analyses from the phase 3 JAVELIN Lung 200 trial - Lung Cancer](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/asset/68f093b2-447e-47f4-b550-8cd068c9f718/gr1.jpg)
Impact of subsequent immune checkpoint inhibitor treatment on overall survival with avelumab vs docetaxel in platinum-treated advanced NSCLC: Post hoc analyses from the phase 3 JAVELIN Lung 200 trial - Lung Cancer
![Avelumab and cetuximab as a therapeutic combination: An overview of scientific rationale and current clinical trials in cancer - Cancer Treatment Reviews Avelumab and cetuximab as a therapeutic combination: An overview of scientific rationale and current clinical trials in cancer - Cancer Treatment Reviews](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/922f2669-ed04-4427-8440-829d8a07afe5/ga1_lrg.jpg)
Avelumab and cetuximab as a therapeutic combination: An overview of scientific rationale and current clinical trials in cancer - Cancer Treatment Reviews
![Avelumab first-line maintenance in locally advanced or metastatic urothelial carcinoma: Applying clinical trial findings to clinical practice - Cancer Treatment Reviews Avelumab first-line maintenance in locally advanced or metastatic urothelial carcinoma: Applying clinical trial findings to clinical practice - Cancer Treatment Reviews](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/e757d8ca-ddc4-46f6-8007-b411e5a50f99/gr3.jpg)
Avelumab first-line maintenance in locally advanced or metastatic urothelial carcinoma: Applying clinical trial findings to clinical practice - Cancer Treatment Reviews
![Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study - The Lancet Oncology Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study - The Lancet Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/0ee290c6-dd2a-4652-aab5-0af7643c80ea/gr1.gif)
Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study - The Lancet Oncology
![Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial - The Lancet Oncology Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial - The Lancet Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/2119314489/2092057779/gr1.gif)
Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial - The Lancet Oncology
![Cancer immunotherapies targeting the PD-1 signaling pathway | Journal of Biomedical Science | Full Text Cancer immunotherapies targeting the PD-1 signaling pathway | Journal of Biomedical Science | Full Text](https://media.springernature.com/full/springer-static/image/art%3A10.1186%2Fs12929-017-0329-9/MediaObjects/12929_2017_329_Fig2_HTML.gif)
Cancer immunotherapies targeting the PD-1 signaling pathway | Journal of Biomedical Science | Full Text
![Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial | Journal for ImmunoTherapy of Cancer Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial | Journal for ImmunoTherapy of Cancer](https://jitc.bmj.com/content/jitc/6/1/7/F1.large.jpg?width=800&height=600&carousel=1)
Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial | Journal for ImmunoTherapy of Cancer
![ASCO 2020: JAVELIN Bladder 100 Phase III Results: Maintenance Avelumab + Best Supportive Care vs BSC Alone After Platinum-Based First-Line Chemotherapy in Advanced Urothelial Carcinoma ASCO 2020: JAVELIN Bladder 100 Phase III Results: Maintenance Avelumab + Best Supportive Care vs BSC Alone After Platinum-Based First-Line Chemotherapy in Advanced Urothelial Carcinoma](https://www.urotoday.com/images/ASCO2020_JAVELIN_Bladder_100_1.png)
ASCO 2020: JAVELIN Bladder 100 Phase III Results: Maintenance Avelumab + Best Supportive Care vs BSC Alone After Platinum-Based First-Line Chemotherapy in Advanced Urothelial Carcinoma
![Avelumab Versus Docetaxel in Patients With Platinum-Treated Advanced NSCLC: 2-Year Follow-Up From the JAVELIN Lung 200 Phase 3 Trial - Journal of Thoracic Oncology Avelumab Versus Docetaxel in Patients With Platinum-Treated Advanced NSCLC: 2-Year Follow-Up From the JAVELIN Lung 200 Phase 3 Trial - Journal of Thoracic Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/bbb64bfa-45bb-4eae-abc3-0baf03416800/gr1.jpg)
Avelumab Versus Docetaxel in Patients With Platinum-Treated Advanced NSCLC: 2-Year Follow-Up From the JAVELIN Lung 200 Phase 3 Trial - Journal of Thoracic Oncology
![Avelumab first-line maintenance in locally advanced or metastatic urothelial carcinoma: Applying clinical trial findings to clinical practice - Cancer Treatment Reviews Avelumab first-line maintenance in locally advanced or metastatic urothelial carcinoma: Applying clinical trial findings to clinical practice - Cancer Treatment Reviews](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/5ff62576-2ca1-4f38-abfe-ec31329d0a75/gr2_lrg.jpg)
Avelumab first-line maintenance in locally advanced or metastatic urothelial carcinoma: Applying clinical trial findings to clinical practice - Cancer Treatment Reviews
![Rationale and design of the POLEM trial: avelumab plus fluoropyrimidine-based chemotherapy as adjuvant treatment for stage III mismatch repair deficient or POLE exonuclease domain mutant colon cancer: a phase III randomised study - Rationale and design of the POLEM trial: avelumab plus fluoropyrimidine-based chemotherapy as adjuvant treatment for stage III mismatch repair deficient or POLE exonuclease domain mutant colon cancer: a phase III randomised study -](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/asset/519acd17-4f0b-4da3-8ec9-5702efbd3df1/gr1.jpg)
Rationale and design of the POLEM trial: avelumab plus fluoropyrimidine-based chemotherapy as adjuvant treatment for stage III mismatch repair deficient or POLE exonuclease domain mutant colon cancer: a phase III randomised study -
![Cancers | Free Full-Text | The Value of PD-L1 Expression as Predictive Biomarker in Metastatic Renal Cell Carcinoma Patients: A Meta-Analysis of Randomized Clinical Trials | HTML Cancers | Free Full-Text | The Value of PD-L1 Expression as Predictive Biomarker in Metastatic Renal Cell Carcinoma Patients: A Meta-Analysis of Randomized Clinical Trials | HTML](https://www.mdpi.com/cancers/cancers-12-01945/article_deploy/html/images/cancers-12-01945-g001-550.jpg)
Cancers | Free Full-Text | The Value of PD-L1 Expression as Predictive Biomarker in Metastatic Renal Cell Carcinoma Patients: A Meta-Analysis of Randomized Clinical Trials | HTML
![Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma - Annals of Oncology Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma - Annals of Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/asset/9528dcf0-5687-436e-8c3c-c20807eed0d7/figs1.jpg)
Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma - Annals of Oncology
![Efficacy and correlative analyses of avelumab plus axitinib versus sunitinib in sarcomatoid renal cell carcinoma: post hoc analysis of a randomized clinical trial - ESMO Open Efficacy and correlative analyses of avelumab plus axitinib versus sunitinib in sarcomatoid renal cell carcinoma: post hoc analysis of a randomized clinical trial - ESMO Open](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/f0969dc3-1cb0-4d0d-a100-02792e0550e7/gr1.jpg)
Efficacy and correlative analyses of avelumab plus axitinib versus sunitinib in sarcomatoid renal cell carcinoma: post hoc analysis of a randomized clinical trial - ESMO Open
![Avelumab Combined with Stereotactic Ablative Body Radiotherapy in Metastatic Castration-resistant Prostate Cancer: The Phase 2 ICE-PAC Clinical Trial - European Urology Avelumab Combined with Stereotactic Ablative Body Radiotherapy in Metastatic Castration-resistant Prostate Cancer: The Phase 2 ICE-PAC Clinical Trial - European Urology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/f5ca38e5-ee49-41c1-bb90-39c97c947ac4/gr1_lrg.jpg)